Key result
Percutaneous renal denervation demonstrated favorable results in second-generation trials for resistant hypertension, supporting a revision of recommendations limiting its use to clinical trials.
Why the study?
Favorable results of second-generation renal denervation trials warrant reviewing the evidence to potentially revise recommendations that limit the procedure to clinical trials.
Does percutaneous renal denervation improve outcomes in patients with resistant hypertension and concomitant diseases?
Does percutaneous renal denervation improve outcomes in patients with resistant hypertension and concomitant diseases?
Second-generation renal denervation trials show favorable results, suggesting the procedure should no longer be restricted solely to clinical trials for resistant hypertension.
May support second-generation RDN for resistant hypertension; leaves open questions on long-term outcomes and optimal patient selection.
<ns3:p>Percutaneous renal denervation (RDN) has been introduced in clinical trials as the possible interventional method of treatment of resistant hypertension more than one decade ago. The results of trials: SYMPLICITY HTN-1 (single-arm), HTN-2 (randomized, single-blinded) and HTN-3 (with sham procedure) are summarized in this article. The author presents the results of second-generation trials with new technologies: Spyral catheter (radiofrequency RDN) and Paradise system (ultrasound RDN). The favorable results of these studies justify the revision of the current recommendations, limiting this method only to clinical trials. Also the studies on RDN applied in atrial fibrillation and obstructive sleep apnea – diseases related to sympathetic nervous system activity – are discussed.</ns3:p>
No takes yet. Share an insight, caveat, or question.
Jacek Kądziela (2020) conducted a review in Resistant hypertension, atrial fibrillation, obstructive sleep apnea. Percutaneous renal denervation (RDN) was evaluated. Percutaneous renal denervation demonstrated favorable results in second-generation trials for resistant hypertension, supporting a revision of recommendations limiting its use to clinical trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: